Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Diabetic Nephropathy
This study aims to evaluate the safety of using allogeneic umbilical cord mesenchymal stem cell therapy as a treatment for diabetic nephropathy, by monitoring the incidence of adverse events and serious adverse events in participants.
Umbilical Cord Mesenchymal Stem Cells
Urogenital Diseases+7
+ Diabetes Mellitus
+ Diabetic Nephropathies
Treatment Study
Summary
Study start date: July 1, 2026
Actual date on which the first participant was enrolled.This clinical trial focuses on diabetic nephropathy, a common complication of diabetes that can lead to severe kidney disease. Despite current treatments, many patients still experience a decline in kidney function. This study explores a new approach using mesenchymal stem cells (MSCs), specifically from umbilical cord tissue, due to their anti-inflammatory and regenerative potential shown in early studies. The goal is to assess the safety and potential benefits of this therapy for individuals with diabetic nephropathy, aiming to improve current treatment options and slow down the disease progression. Participants in this trial will receive the treatment through an intra-renal injection. The study will monitor any adverse events or reactions to the therapy, both locally and throughout the body, to evaluate its safety. The primary outcome is to measure changes in kidney function and inflammatory markers over time, providing insights into the effects of MSC therapy on diabetic nephropathy. This research offers a significant step towards developing new interventions for chronic kidney disease, contributing valuable data to the emerging field of regenerative nephrology.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.10 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 30 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location